Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO neoadjuvant Keytruda in vulvar squamous cell carcinoma
2024-512862-32-00Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in vulvar squamous cell carcinoma (VSCC), sponsored by Leiden University Medical Center. Primary endpoints: Clinical efficacy of neoadjuvant PD-1 blockade in vulvar squamous cell carcinoma and Activation, proliferation and migration of CD4+CD39+PD-1+ intratumoral T-cell population. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on 2024-512862-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512862-32-00.